Cargando…

DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia

Reduced expression of the uptake transporter, OCTN1 (SLC22A4), has been reported as a strong predictor of poor event‐free and overall survival in multiple cohorts of patients with acute myeloid leukemia (AML) receiving the cytidine nucleoside analog, cytarabine (Ara‐C). To further understand the mec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buelow, Daelynn R., Anderson, Jason T., Pounds, Stanley B., Shi, Lei, Lamba, Jatinder K., Hu, Shuiying, Gibson, Alice A., Goodwin, Emily A., Sparreboom, Alex, Baker, Sharyn D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877866/ https://www.ncbi.nlm.nih.gov/pubmed/32905646 http://dx.doi.org/10.1111/cts.12861

Ejemplares similares

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression
por: Drenberg, CD, et al.
Publicado: (2016)

Proteomics: a new era in pediatric acute myeloid leukemia research
por: Lamba, Jatinder K., et al.
Publicado: (2022)

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia
por: Bhise, Neha S., et al.
Publicado: (2019)

Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML
por: Bargal, Salma A., et al.
Publicado: (2018)

Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation
por: Li, Yang, et al.
Publicado: (2021)

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia
por: Lamba, Jatinder K., et al.
Publicado: (2018)

Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia
por: Lamba, Jatinder K., et al.
Publicado: (2018)

A 6-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia
por: Elsayed, Abdelrahman H., et al.
Publicado: (2019)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial
por: Rubnitz, Jeffrey E., et al.
Publicado: (2009)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022)

MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients
por: Bhise, Neha S., et al.
Publicado: (2016)

CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints
por: Cao, Xueyuan, et al.
Publicado: (2016)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities
por: Li, Yang, et al.
Publicado: (2022)

MiR-184 regulates insulin secretion through repression of Slc25a22
por: Morita, Sumiyo, et al.
Publicado: (2013)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
por: Jost, Felix, et al.
Publicado: (2019)

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
por: Jaruskova, Monika, et al.
Publicado: (2017)

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
por: Drenberg, Christina D., et al.
Publicado: (2019)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
por: Bhatnagar, Bhavana, et al.
Publicado: (2023)

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML
por: Stockard, Bradley, et al.
Publicado: (2021)

Genetic and Epigenetic Regulation of the Organic Cation Transporter 3, SLC22A3
por: Chen, Ligong, et al.
Publicado: (2012)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review
por: Marrero, Richard J., et al.
Publicado: (2023)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML
por: Lamba, Jatinder K., et al.
Publicado: (2020)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oc2eb9k4cspr3vpe1ppspbo791